WO2003039461A3 - Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof - Google Patents

Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof Download PDF

Info

Publication number
WO2003039461A3
WO2003039461A3 PCT/US2002/035147 US0235147W WO03039461A3 WO 2003039461 A3 WO2003039461 A3 WO 2003039461A3 US 0235147 W US0235147 W US 0235147W WO 03039461 A3 WO03039461 A3 WO 03039461A3
Authority
WO
WIPO (PCT)
Prior art keywords
nitrogen
saccharide
benzyl
tocotrienols
chroman
Prior art date
Application number
PCT/US2002/035147
Other languages
French (fr)
Other versions
WO2003039461A2 (en
Inventor
Bob G Sanders
Kimberly Kline
Weiping Yu
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Priority to AU2002353971A priority Critical patent/AU2002353971A1/en
Publication of WO2003039461A2 publication Critical patent/WO2003039461A2/en
Publication of WO2003039461A3 publication Critical patent/WO2003039461A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols

Abstract

The present invention provides an antiproloferative compound having a structural formula where X and Y independently are oxygen, nitrogen or sulfur; R1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, carboxylate, carboxamide, ester, thioamide, thiolacid, thiolester, saccharide, alkoxy-linked saccharide, amine, sulfonate, sulfate, phosphate, alcohol, ethers or nitriles; R?2 and R3¿ are hydrogen or R4; R4 is methyl, benzyl, carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide or amine; and R5 is alkenyl; where when Y is nitrogen, said nitrogen is substituted with R6, wherein R6 is h<drogen or methyl. Also provided are methods for treating a cell proliferative disease and for inducing apoptosis in a cell comprising administering this compound is also provided.
PCT/US2002/035147 2001-11-05 2002-11-01 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof WO2003039461A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002353971A AU2002353971A1 (en) 2001-11-05 2002-11-01 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/008,066 US6703384B2 (en) 1998-09-23 2001-11-05 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US10/008,066 2001-11-05

Publications (2)

Publication Number Publication Date
WO2003039461A2 WO2003039461A2 (en) 2003-05-15
WO2003039461A3 true WO2003039461A3 (en) 2003-11-13

Family

ID=21729641

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/035147 WO2003039461A2 (en) 2001-11-05 2002-11-01 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof

Country Status (3)

Country Link
US (5) US6703384B2 (en)
AU (1) AU2002353971A1 (en)
WO (1) WO2003039461A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841342B2 (en) 2002-08-09 2014-09-23 Vital Health Sciences Pty. Ltd. Carrier
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US9314527B2 (en) 2010-03-30 2016-04-19 Phosphagenics Limited Transdermal delivery patch
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703384B2 (en) 1998-09-23 2004-03-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
ATE382615T1 (en) 2000-02-11 2008-01-15 Res Dev Foundation TOCOPHEROLS, TOCOTRIENOLS, OTHER CHROMES AND SIDE CHAIN DERIVATIVES AND THE USE THEREOF
EP1339413B1 (en) * 2000-11-14 2009-10-07 Vital Health Sciences Pty Ltd. Compositions comprising complexes of phosphate derivatives of tocopherol
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
US8008345B2 (en) * 2001-07-27 2011-08-30 Vital Health Sciences Pty. Ltd. Dermal therapy using phosphate derivatives of electron transfer agents
CN1604772A (en) * 2001-12-13 2005-04-06 生命健康科学有限公司 Transdermal transport of compounds
US20030236301A1 (en) * 2001-12-19 2003-12-25 Bob Sanders Liposomal delivery of vitamin E based compounds
EP1589964B1 (en) * 2003-01-17 2011-11-23 Vital Health Sciences Pty Ltd. Compounds having anti-proliferative properties
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
US20050080109A1 (en) * 2003-10-09 2005-04-14 Papas Andreas M. Gamma-tocopherol and gamma-tocotrienol therapy for multiple sclerosis
JP4847437B2 (en) * 2004-03-03 2011-12-28 バイタル ヘルス サイエンシズ プロプライアタリー リミティド Alkaloid preparation
US20060165769A1 (en) * 2004-09-30 2006-07-27 Hyatt John A Pharmaceutical formulations containing vitamin E TPGS molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations
EP1858508A4 (en) * 2005-03-03 2009-01-07 Vital Health Sciences Pty Ltd Compounds having anti-cancer properties
CA2631653A1 (en) * 2005-12-23 2007-06-28 Vital Health Sciences Pty Ltd. Compounds having cytokine modulating properties
US20080009545A1 (en) * 2006-02-21 2008-01-10 The Ohio State University Research Foundation Anticancer agents
EP2004159A1 (en) * 2006-03-15 2008-12-24 Biovitrum AB (publ) Autoimmune conditions and nadph oxidase defects
WO2007143081A2 (en) * 2006-06-02 2007-12-13 The Ohio State University Research Foundation Therapeutic agents for the treatment of lymphoid malignancies
JP5092158B2 (en) * 2006-12-01 2012-12-05 独立行政法人放射線医学総合研究所 Radioprotectants containing tocopherols or ester derivatives of tocotrienols as active ingredients
US20100292316A1 (en) * 2007-07-18 2010-11-18 Research Development Foundation Improved therapeutic methods and compositions comprising chroman ring compounds
EP2419414A4 (en) * 2009-04-13 2013-12-04 Univ Ohio State Res Found Protein phosphatase 2a-activating agents
WO2010121111A1 (en) * 2009-04-17 2010-10-21 The Ohio State University Research Foundation Antiadhesion agents
WO2010124223A1 (en) * 2009-04-23 2010-10-28 First Tech International Limited Anti-cancer tocotrienol analogues and associated methods
US9180113B2 (en) 2009-09-01 2015-11-10 First Tech International Limited Tocotrienol compositions
WO2011097481A1 (en) 2010-02-05 2011-08-11 First Tech International Limited Tocotrienol esters
US10071030B2 (en) 2010-02-05 2018-09-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
US8309768B2 (en) 2010-11-29 2012-11-13 The Ohio State University Research Foundation FTY720-derived anticancer agents
US8816071B2 (en) * 2011-12-02 2014-08-26 First Tech International Limited Tocotrienol derivatives and associated methods
KR20150024888A (en) 2012-06-08 2015-03-09 더 오하이오 스테이트 유니버시티 Treating burn and scar injury using tocotrienol
PL3041831T3 (en) 2013-09-06 2021-07-19 Research Development Foundation Alpha-tea salt forms: compositions and uses for treating disease
US9993456B2 (en) 2013-09-13 2018-06-12 The Board Of Trustees Of The University Of Arkansas Preparation and use of a composition for prevention and mitigation of the effects of radiation
US20160324914A1 (en) 2015-05-05 2016-11-10 Tocol Pharmaceuticals, Llc Use of rice bran oil distillate extract for prevention and mitigation of the effects of radiation
CA3007587C (en) 2015-12-09 2023-12-05 Phosphagenics Limited Pharmaceutical formulation
KR102644587B1 (en) * 2015-12-24 2024-03-07 (주)아모레퍼시픽 Pseudoceramide compounds and preparation method thereof
KR102647670B1 (en) 2016-12-21 2024-03-15 아베초 바이오테크놀로지 리미티드 method
CN110337495B (en) 2017-02-06 2024-03-29 日产化学株式会社 Single-stranded oligonucleotides
CN111635390A (en) * 2020-06-30 2020-09-08 江南大学 Low-foam alpha-tocopherol surfactant and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114957A (en) * 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
US5336485A (en) * 1988-01-29 1994-08-09 Center For Innovative Technology Method for protecting animals against tacrine induced cytotoxic injury using sterol compounds
US5919818A (en) * 1991-11-22 1999-07-06 Lipogenics, Inc. Tocotrienols and tocotrienol-like compounds and methods for their use
US6133312A (en) * 1997-03-04 2000-10-17 Wisconsin Alumni Research Foundation Method of suppressing tumor growth with combinations of isoprenoids and statins

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5118954B2 (en) 1972-02-04 1976-06-14
CS172015B1 (en) 1974-05-12 1976-12-29
US4181725A (en) 1977-05-02 1980-01-01 The Regents Of The University Of Michigan Method for alleviating psoriasis
EP0008573A1 (en) 1977-12-16 1980-03-05 Nisshin Flour Milling Co., Ltd. Anti-tumor agent
JPS5484034A (en) 1977-12-16 1979-07-04 Nisshin Flour Milling Co Ltd Anti-tumor agent
JPS5573690A (en) 1978-11-28 1980-06-03 Eisai Co Ltd Novel penicillin derivative and antibacterial comprising it
JPS6056155B2 (en) 1978-12-04 1985-12-09 エーザイ株式会社 Chromanyloxy fatty acid congeners
JPS57175186A (en) 1981-04-20 1982-10-28 Fujimoto Seiyaku Kk Novel vitamin e derivative and its preparation
US4457918A (en) 1982-05-12 1984-07-03 The General Hospital Corporation Glycosides of vitamins A, E and K
JPS59157085A (en) 1983-02-28 1984-09-06 Green Cross Corp:The Benzazepine derivative
DE3309159A1 (en) 1983-03-15 1984-09-20 Basf Ag, 6700 Ludwigshafen NEW OPTICALLY ACTIVE CHROME DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND NEW INTERMEDIATE PRODUCTS
US4873088A (en) 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US4617317A (en) 1984-10-31 1986-10-14 Bennet Justin D Method of treating ulcerative colitis
WO1986006959A1 (en) 1985-05-22 1986-12-04 Liposome Technology, Inc. Liposome inhalation method and system
US4665204A (en) 1985-06-27 1987-05-12 Henkel Corporation Diester derivatives of tocopherol
JPS63303049A (en) 1987-06-04 1988-12-09 Shinagawa Refract Co Ltd Fiber-reinforced vitreous thermal spraying material
JPS6441727A (en) 1987-08-07 1989-02-14 Toshiba Corp Cooking unit
US5610180A (en) 1988-01-29 1997-03-11 Virginia Commonwealth University Ionizable congeners of aromatic and aliphatic alcohols as anti-leukemia agents
JPH01211578A (en) 1988-02-19 1989-08-24 Fuji Kagaku Kogyo Kk Vitamin e derivative and production thereof
US5260294A (en) 1988-08-09 1993-11-09 Hoffman-La Roche Inc. Chromanes and their pharmaceutical compositions and methods
JPH02149577A (en) 1988-11-30 1990-06-08 Eisai Co Ltd Tocopherol aminoalkylcarboxylic acid ester and salt thereof
JPH03206089A (en) 1990-01-05 1991-09-09 Eisai Co Ltd New vitamin e derivative and production thereof
DE4014708C2 (en) 1990-05-08 1994-03-10 Heidelberger Druckmasch Ag Procedure for determining register errors
FR2672601B1 (en) 1991-02-08 1994-10-14 Synthelabo BENZO-1,5-THIAZEPINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.
JPH05213982A (en) 1991-03-26 1993-08-24 Dainippon Ink & Chem Inc Oligosaccharide tocopherol glycoside, sulfated oligosaccharide tocopherol glycoside and antiviral agent comprising the same as active ingredient
FR2676056B1 (en) 1991-05-03 1993-07-16 Adir NOVEL BENZOPYRAN DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
HU210499B (en) 1991-05-30 1995-04-28 Bristol Myers Squibb Co Process for preparing 6-o-alkylelsamicin a deriv.s and pharmaceutical compn.s contg. them
CH681152A5 (en) 1991-06-04 1993-01-29 Marigen S.A. NEW biosurfactants AND ESTERS AND antitumoral phosphatides WITH VITAMIN D AND VITAMIN E COMPOUNDS, THEIR PRODUCTION AND UPDATE SPONTANEOUS DISPERSIBLE CONCENTRATES.
EP0636618A1 (en) 1991-06-04 1995-02-01 Marigen S.A. Spontaneously dispersible concentrates and microemulsions with vitamin E compounds for the preparation of medicaments with anti-tumour activity
US5135945A (en) 1991-06-05 1992-08-04 Merrell Dow Pharmaceuticals Inc. Cholesterol-lowering tocopherol analogs
US5545660A (en) * 1992-04-07 1996-08-13 Merrell Pharmaceuticals Inc. Hydrazide derivatives of 3,4-dihydro-2H-1-benzopyrans
JPH065519A (en) 1992-06-17 1994-01-14 Murata Mfg Co Ltd Ecr type ion source
GB9214603D0 (en) 1992-07-09 1992-08-19 Taiho Pharmaceutical Co Ltd 4-oxa-1-azabicyclo (3,2,0) heptan-7-one derivatives as antitumor agents
FR2695387B1 (en) 1992-09-09 1994-10-21 Adir New benzopyran compounds, process for their preparation and pharmaceutical compositions containing them.
US5403834A (en) 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
IT1256264B (en) 1992-12-31 1995-11-29 Lifegroup Spa N-HYDROXYAMINE N-ACIL DERIVATIVES EQUIPPED WITH SCAVENGER ACTIVITIES AND USABLE IN ACUTE AND CHRONIC PATHOLOGIES RELATED TO PHENOMENA OF PEROXIDATION AND INFLAMMATION
US5545398A (en) * 1993-01-13 1996-08-13 Perricone; Nicholos V. Method and compositions for topical application to the skin of tocotrienol for prevention and/or treatment of skin damage
DE4304303C2 (en) 1993-01-22 1997-01-30 Pacific Corp Vitamin E derivatives with a quaternary nitrogen atom, process for their preparation and cosmetic compositions containing the same
JPH07138159A (en) 1993-11-19 1995-05-30 Kuraray Co Ltd Skin disease-treating agent containing vitamin e derivative as active ingredient
CA2152693A1 (en) 1994-08-05 1996-02-06 Kazumi Ogata Therapeutic composition for pancreatitis
US5596095A (en) 1994-12-12 1997-01-21 Procept, Inc. Formation and utility of sulfonic acid protecting groups
US5670255A (en) 1995-01-23 1997-09-23 Ppg Industries, Inc. Antioxidant compositions for coating substrates, substrates coated with the same and methods for inhibiting the oxidation of such compositions applied to a substrate
DE19504398A1 (en) 1995-02-10 1996-08-14 Beiersdorf Ag Tocopherylglycoside, their preparation and their use as surfactants, as antioxidants and as a cell aging preventive agent in cosmetic or pharmaceutical preparations
DE19523079A1 (en) 1995-06-26 1997-01-02 Basf Ag Esters and amides of 9 (Z) -retinoic acid
CA2179940A1 (en) 1995-07-18 1997-01-19 Kazumi Ogata Antiallergic composition comprising a phosphoric diester compound
US5798356A (en) 1995-08-07 1998-08-25 Alcon Laboratories, Inc. Angiostatic compounds
CA2186654A1 (en) 1995-10-13 1997-04-14 Masayuki Nakamura Phosphoric diester
JPH09301953A (en) 1996-03-12 1997-11-25 Sanwa Kagaku Kenkyusho Co Ltd Malonic acid diamide derivative and use thereof
JPH104489A (en) 1996-04-19 1998-01-06 Nikon Corp Picture input device
JPH09301969A (en) * 1996-05-15 1997-11-25 Fuji Photo Film Co Ltd Chroman-based compound and heat-sensitive recording material using the same
DE19624731A1 (en) * 1996-06-21 1998-01-02 Berkenhoff Gmbh Alloy, especially for the manufacture of eyeglass frames, jewelry, etc.
US5827878A (en) 1996-07-01 1998-10-27 Nisshin Flour Milling Co., Ltd. Pharmaceutical composition for the treatment of leukemia containing 9-cis-retinoic acid-α-tocopherol ester
US6022560A (en) 1996-08-27 2000-02-08 Clarion Pharmaceuticals Inc. Pharmaceutical compositions, novel uses, and novel form of α-tocopherylphosphocholine
FR2754713B1 (en) 1996-10-22 1999-01-08 Roc Sa USE OF COMPLEXES FOR THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF SENSITIVE SKIN, PREPARATION METHOD AND HYPOALLERGENIC COMPOSITIONS
CA2220541A1 (en) 1997-11-07 1999-05-07 Mcgill University Analogs of vitamin e
US5917060A (en) 1997-12-17 1999-06-29 Basf Aktiengesellschaft Preparation of chromanyl derivatives
NZ510732A (en) 1998-09-23 2004-01-30 Res Dev Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US6703384B2 (en) * 1998-09-23 2004-03-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US6770672B1 (en) * 1998-09-23 2004-08-03 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
FR2784988B1 (en) 1998-10-23 2002-09-20 Adir NOVEL DIHYDRO AND TETRAHYDROQUINOLEINIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5990322A (en) 1999-03-09 1999-11-23 Sk Corporation Alpha-tocopherol cyclopropylates, the new vitamin E derivatives and method for producing the same
US6127382A (en) 1999-08-16 2000-10-03 Allergan Sales, Inc. Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
WO2001045306A1 (en) * 1999-12-17 2001-06-21 Corning O.T.I., Inc Method and device for locking the wavelength of an optical signal
ATE382615T1 (en) 2000-02-11 2008-01-15 Res Dev Foundation TOCOPHEROLS, TOCOTRIENOLS, OTHER CHROMES AND SIDE CHAIN DERIVATIVES AND THE USE THEREOF
US20030236301A1 (en) 2001-12-19 2003-12-25 Bob Sanders Liposomal delivery of vitamin E based compounds
US7045324B2 (en) 2002-04-19 2006-05-16 Research Development Foundation Tocopherol associated protein and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336485A (en) * 1988-01-29 1994-08-09 Center For Innovative Technology Method for protecting animals against tacrine induced cytotoxic injury using sterol compounds
US5114957A (en) * 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
US5919818A (en) * 1991-11-22 1999-07-06 Lipogenics, Inc. Tocotrienols and tocotrienol-like compounds and methods for their use
US6133312A (en) * 1997-03-04 2000-10-17 Wisconsin Alumni Research Foundation Method of suppressing tumor growth with combinations of isoprenoids and statins

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841342B2 (en) 2002-08-09 2014-09-23 Vital Health Sciences Pty. Ltd. Carrier
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US9314527B2 (en) 2010-03-30 2016-04-19 Phosphagenics Limited Transdermal delivery patch
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound

Also Published As

Publication number Publication date
US7300954B2 (en) 2007-11-27
US20040097431A1 (en) 2004-05-20
US20100303899A1 (en) 2010-12-02
US8664264B2 (en) 2014-03-04
US7718814B2 (en) 2010-05-18
US20120251616A1 (en) 2012-10-04
US6703384B2 (en) 2004-03-09
US8148424B2 (en) 2012-04-03
US20020107207A1 (en) 2002-08-08
WO2003039461A2 (en) 2003-05-15
AU2002353971A1 (en) 2003-05-19
US20080161349A1 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
WO2003039461A3 (en) Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
ZA200102057B (en) Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof.
WO2002064547A3 (en) Isophthalic acid derivatives as matrix metalloproteinase inhibitors
ES2182234T3 (en) METALOPROTEASE INHIBITORS.
MY118904A (en) 4-oxo-1, 4-dihydro-3-quinolinecarboxamides as antiviral agents
CA2379747A1 (en) Novel succinate derivative compounds useful as cysteine protease inhibitors
NZ514662A (en) Amine derivatives
ATE273280T1 (en) 2-PYRIDINYLGUANIDINE AS UROKINASE INHIBITORS
EP1371640A4 (en) Novel a-lipoic acid derivative and use thereof
AP2001002205A0 (en) Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase.
WO2004063330A3 (en) (2-carboxamido) (3-amino) thiophene compounds
TR200400003T4 (en) (S) -2-Ethoxy -3-4- (2-4-Methanesulfonyloxyphenyl ethoxy) propanoic acid
DK0559533T3 (en) Process for the preparation of beta-lactam derivative and its synthetic intermediate
DK0695755T3 (en) pyrrolocarbazoles
ES2154605A1 (en) New benzimidazole-arylpiperazine derivatives with affinity for serotoninergic receptors 5-HT1A and 5HT3, used for treating CNS disorders
WO2003020703A1 (en) Cyclic amine compound
EP1357124A4 (en) Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient
AU9025601A (en) Cephem compounds and esbl-detecting reagents containing the same
ATE297902T1 (en) SULFONYL PYRIDAZINONE DERIVATIVES FOR USE AS ALDOSE REDUCTASE INHIBITORS
HK1066225A1 (en) Processes for preparing pesticidal intermediates
CA2058398A1 (en) 1,4 Benzothiazine-2-Acetic Acid Derivatives, Processes for Production Thereof
MXPA03012073A (en) Heterocyclic amide derivatives.
AU2178199A (en) Azetidinecarboxamide derivatives for the treatment of cns disorders
IL130052A0 (en) Method of treating glaucoma and ischemic retinopathy
ES2166710A1 (en) Novel heterocyclic compounds with anti-inflammatory activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP